Earlier this month, 44 states filed a sweeping lawsuit that accused 20 generic drug makers, including large players such as Teva Pharmaceutical, and 15 current and former executives of a widespread price-fixing conspiracy. This was the second such lawsuit over the past three years that alleged schemes in which one company would decide to raise prices on a particular medicine and others would follow suit. The 524-page lawsuit also detailed how companies would agree to divide a market, rather than compete by lowering prices. In some instances, the coordinated price increases were over 1,000%. The lawsuits come amid a national debate over rising drug costs.

We spoke with Joseph Nielsen, an assistant attorney general in Connecticut, which has taken the lead on these cases, about some of the details and what to expect next. This is an edited version of our conversation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy